GE HealthCare collaborates with Diagnoly to provide AI-powered fetal ultrasound technology to clinicians

USA—GE HealthCare has entered into a strategic collaboration with Diagnoly, a deeptech company specializing in prenatal screening solutions, to integrate artificial intelligence capabilities into fetal ultrasound examinations.

The partnership centers on incorporating Diagnoly’s Fetoly platform into GE HealthCare’s established Voluson women’s health ultrasound systems, marking a significant advancement in prenatal diagnostic technology.

The collaboration aims to accelerate the deployment of AI-enabled screening tools that can support healthcare providers in delivering more comprehensive and standardized fetal examinations.

This integration represents a convergence of GE HealthCare’s market-leading ultrasound hardware with Diagnoly’s innovative software solutions, creating an enhanced diagnostic ecosystem for maternal and fetal care.

Real-time AI assistance for comprehensive fetal screening

Fetoly operates as a real-time artificial intelligence solution that guides clinicians through comprehensive, standardized fetal ultrasound examinations.

The platform aligns with protocols established by the International Society of Ultrasound in Obstetrics and Gynaecology (ISUOG), ensuring that examinations meet internationally recognized clinical standards.

The technology provides AI-powered diagnostic support specifically designed for fetal heart and brain analysis, two critical areas in prenatal assessment.

Throughout the examination process, Fetoly continuously verifies that the scan meets completeness and quality criteria, offering clinicians immediate feedback on their imaging work.

This real-time validation helps ensure that no critical anatomical structures are overlooked during the examination.

The integration of Fetoly into the Voluson product portfolio enhances the existing capabilities of these ultrasound systems, providing clinicians with additional tools to deliver optimal patient care.

The technology acts as an intelligent assistant that works alongside healthcare providers, supporting their clinical decision-making without replacing their expertise.

Regulatory approval and current availability

Fetoly has secured regulatory clearances from major health authorities, including US Food and Drug Administration (FDA) 510(k) clearance and European CE marking.

These approvals demonstrate that the technology meets rigorous safety and efficacy standards required for clinical use in these key markets.

Healthcare providers can currently access Fetoly through the Voluson Solution Store, where the AI application is available for free trial.

The platform is also accessible on other major mobile app platforms, making it widely available to clinicians who want to explore its capabilities before full implementation.

Industry leaders emphasize AI’s transformative potential

Gerald Seifriedsberger, general manager of women’s health ultrasound at GE HealthCare, emphasized the transformative role of artificial intelligence in modern healthcare delivery.

He positioned GE HealthCare as an industry leader committed to bringing AI-powered innovations to frontline clinicians.

Seifriedsberger noted that the collaboration with Diagnoly expands the company’s ability to integrate advanced AI-based screening support into Voluson ultrasound systems, ultimately helping to elevate care standards for women and their babies.

Ivan Voznyuk, co-founder and CEO of Diagnoly, highlighted the complexity inherent in obstetric ultrasound imaging.

He pointed to a concerning statistic: up to 50% of fetal abnormalities remain undetected during pregnancy under current screening practices.

Voznyuk expressed his belief that artificial intelligence can play a transformative role in making high-quality screening more accurate, accessible, and consistent across different healthcare settings and practitioner skill levels.

The Diagnoly CEO stated that integrating Fetoly into trusted Voluson ultrasound systems reflects both companies’ shared commitment to supporting clinicians in real-time with tools that can help improve maternal and fetal outcomes.

This alignment of values and objectives forms the foundation of the partnership between the two organizations.

Broader context of innovation

Earlier this week, GE HealthCare achieved simultaneous FDA clearance and European CE marking for Allia Moveo, an imaging system designed to provide healthcare centers with increased procedural flexibility within interventional suites.

This recent regulatory success demonstrates GE HealthCare’s ongoing commitment to advancing medical imaging technology across multiple clinical specialties and care settings.